Thoratec Granted Approval for Circulatory Support Device
Posted on: Tuesday, 22 April 2008, 09:01 CDT
Thoratec has received FDA approval of its premarket approval application, allowing the use of its HeartMate II Left Ventricular Assist System as a bridge-to-transplantation in patients suffering from advanced-stage heart failure.
The approval follows a successful clinical trial involving more than 450 bridge-to-transplantation (BTT) patients, including those enrolled under continued access protocols, and a unanimous recommendation for approval from the FDA Circulatory System Devices Advisory Panel in November, 2007.
The approval allows the HeartMate II to be used to treat small patients (BSA < 1.5) based on body habitus if the treating clinician believes that the patient could benefit from the device. In addition, Thoratec will conduct a post-market study that includes a concurrent comparator. The study will follow 169 HeartMate II patients until outcome, or one year - whichever comes first - and gather data regarding survival, adverse events, patient gender, small patients and anticoagulation levels.
Gary Burbach, president and CEO of Thoratec, said: "The HeartMate II is the first continuous flow device to receive FDA approval for this intended use in the US, representing a milestone in the treatment of advanced-stage heart failure patients and for the clinicians who treat them."
Source: Datamonitor
Related Articles
- Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
- Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I/II Clinical Trial of CPI-613 in Cancer Patients By US FDA
- Crystallize Your Business Decisions With Drug Approval Trends at the FDA and EMEA Report
- Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
- Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
- Former Drug Czar McCaffrey Asks Congressional Leaders to Assure Health Providers Approve Patient Decisions in Substance Abuse Parity Bill Moving in Congress
- Thoratec Completes Filing of PMA Seeking Bridge-to-Transplantation Approval for HeartMate(R) II
- Cyberonics Provides TRD Post Approval Patient Access and Outcomes Update
- Eli Lilly and Company Announces Approvable Letter Issued By FDA for Arxxant(TM) (Ruboxistaurin Mesylate)
- NovaDel Pharma Receives Approvable Letter From the FDA for NitroMist -- Nitroglycerin Lingual Aerosol--
 |
 |
User Comments (0)
RSS Feeds